US LNG exports surge but will buyers in China turn up?
In a recent transaction, Joshua R. Disbrow, the Chief Executive Officer of Aytu BioPharma, Inc. (NASDAQ:AYTU), purchased 15,000 shares of the company’s common stock. This acquisition, which occurred on February 28, 2025, was executed through multiple open market transactions at prices ranging from $1.29 to $1.30 per share, with a weighted average price of approximately $1.30 per share. The total value of the purchase amounted to $19,500. According to InvestingPro data, this insider purchase comes as the stock trades near its 52-week low of $1.23, with analysts setting an $8.00 price target for the shares.
Following this transaction, Disbrow’s direct ownership in Aytu BioPharma increased to 86,591 shares. This move reflects his continued investment in the company, which is known for its pharmaceutical preparations. Aytu BioPharma is headquartered in Denver, Colorado. With a market capitalization of $7.71 million and an overall "FAIR" financial health rating from InvestingPro, the company appears undervalued based on comprehensive Fair Value analysis. Subscribers to InvestingPro can access 10+ additional insights and a detailed Pro Research Report covering what really matters about this pharmaceutical company.
In other recent news, Aytu BioPharma reported a decrease in net revenue for Q2 2025, primarily due to challenges within its ADHD portfolio. The company posted net revenue of $16.2 million, down from $18.7 million year-over-year, with ADHD portfolio revenue decreasing by 17% to $13.8 million. Despite the decline, Aytu BioPharma achieved a net income of $800,000, equating to $0.13 per share. The pediatric segment, however, showed resilience with net revenue increasing to $2.4 million from $2.1 million year-over-year. The company is focusing on cost-saving measures, having reduced G&A expenses by 37% over two years. In addition, Aytu BioPharma is actively pursuing business development opportunities in CNS/psychiatry and pediatrics sectors. The company aims for positive cash flows and continues to leverage its A2RxConnect platform to support prescription growth and patient access.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.